Table 5.

Group B inner and central lesions location: DEV and OAR doses achieved with each technique. The average ± 1 standard deviation was over 10 patients that failed one or more RAPID trail dose constraints (p‐value > 0.05 was not considered significant).

Parameter (Objective)	3D CRT	CG‐Darc	RapidArc	p‐value CG‐Darc vs. 3D CRT	p‐value CG‐Darc vs. RapidArc	p‐value RapidArc vs. 3D CRT
DEV
HI (close to 0)	$0.11\pm 0.04$	$0.09\pm 0.02$	$0.13\pm 0.02$	−	$<0.001$	−
IPCI (close to 1)	$0.39\pm 0.11$	$0.49\pm 0.08$	$0.58\pm 0.10$	0.002	0.005	$<0.001$
$\mathrm{V}95\%(>95\%)$	$95.4\pm 4.1$	$97.0\pm 1.7$	$93.5\pm 2.3$	−	0.001	−
Max. Dose, %	$106.8\pm 2.4$	$105.5\pm 1.6$	$107.5\pm 1.5$	−	0.03	−
Ipsilateral Breast
V50% ($<60\%$)	$48.3\pm 15.3$	$45.2\pm 10.7$	$41.1\pm 12.2$	−	0.02	0.01
V95% ($<35\%$)	$22.9\pm 11.2$	$18.0\pm 8.2$	$14.3\pm 6.5$	0.01	0.01	0.001
V100% ($<35\%$)	$10.6\pm 5.0$	$7.9\pm 3.7$	$6.7\pm 3.4$	0.02	−	0.006
Mean dose, Gy	$18.7\pm 5.2$	$17.5\pm 4.2$	$15.4\pm 4.2$	−	0.001	$<0.001$
Ipsilateral Lung
V10% ($<20\%$)	$25.2\pm 19.1$	$15.1\pm 5.8$	$27.3\pm 11.0$	−	$<0.001$	−
V30% ($<10\%$)	$10.7\pm 5.9$	$6.0\pm 2.6$	$12.0\pm 5.7$	0.02	0.001	−
V20Gy ($<3\%$)	$6.0\pm 3.5$	$3.0\pm 1.3$	$5.9\pm 3.6$	0.01	0.01	−
Mean Dose, Gy	$4.3\pm 2.2$	$2.4\pm 1.2$	$4.3\pm 1.7$	0.02	$<0.001$	−
Contralateral Breast
Max. Dose($<5\%$)	$9.2\pm 3.7$	$4.3\pm 0.7$	$6.3\pm 1.5$	0.003	$<0.001$	0.02
Heart
V5%, %	$12.9\pm 29.2$	$3.1\pm 5.7$	$5.0\pm 8.6$	−	0.04	−
Skin
Mean Dose, Gy	$13.8\pm 5.0$	$12.1\pm 3.9$	$9.7\pm 4.6$	0.03	0.01	$<0.001$
D2%,Gy	$36.7\pm 2.0$	$35.6\pm 1.8$	$34.9\pm 2.3$	0.01	−	0.005